Intravenous immunoglobulin in the treatment of primary trigeminal neuralgia refractory to carbamazepine: A study protocol[ISRCTN33042138]

BMC Neurology

Volumn 3, Issue , 2003, Pages

  Goebel, Andreas ^a,b   Moore, Andrew ^a   Weatherall, Rosamund ^a   Roewer, Norbert ^b   Schedel, Robert ^b   Sprotte, Guenter ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; IMMUNOGLOBULIN; PLACEBO;

ADD ON THERAPY; ADULT; ANALGESIA; ARTICLE; CHRONIC PAIN; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MEDICAL RESEARCH; METHODOLOGY; MULTICENTER STUDY; PAIN ASSESSMENT; PATIENT MONITORING; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TRIGEMINUS NEURALGIA;

FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PAIN MEASUREMENT; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TRIGEMINAL NERVE DISEASES;

EID: 2642544252     PISSN: 14712377     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2377-3-1     Document Type: Article

References (23)

1. Brisman R Surgical Treatment of Trigeminal Neuralgia. Seminars in Neurology 1997, 17(4):367-372
2. Barker FG, Jannetta PJ, Bissonette DJ, Larkings MV and Hae Dong Joh The long-term outcome of microvascular decompression for trigeminal neuralgia. The New England Journal of Medicine 1996, 334(17):1077-1083
3. Merskey H, Bogduk N and editors Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Seattle IASP Press 1994, 59-60
4. McQuay H, Carroll D, Jadad AR, Wiffen P and Moore A Anticonvulsant drugs for management of pain: a systematic review. British Medical Journal 1995, 311:1047-1052
5. Goebel A, Netal S, Schedel R and Sprotte G Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Medicine 2002, 3(2):119-127
6. Goebel A, Netal S, Schedel R and Sprotte G Human immunoglobulin (IVIG) treatment of trigeminal neuralgia refractory to carbamazepine-therapy. European Journal of Neuroscience (suppl.) 2000, 12(11):360
7. Latov N, Chaudhry V, Koski CL, Lisak RP, Apatoff BR, Hahn AF and Howard JF Jr Use of intravenous gammaglobulins in neuroimmunologic diseases. The Journal of Allergy and Clinical Immunology 2001, 108(4 suppl):126-32
8. Dalakas MC Intravenous Immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle-Nerve 1999, 22:1479-1497
9. Noseworthy JH, O'Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA and Auger RG A randomised trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001, 56(11):1514-1522
10. Noseworthy JH, O'Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stop-Smith KA and Harper CM IV immunoglobulin does not reverse established weakness in MS. Neurology 2000, 55(8):1135-1143
11. Nurmikko TJ and Eldridge PR Trigeminal neuralgia - pathophysiology, diagnosis and current treatment. British Journal of Anaesthesia 2001, 87:117-132
12. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW and Mullens EL Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double - blind placebo controlled crossover trial. Pain 1997, 73:223-230
13. Sindrup SH and Jensen TS Pharmacotherapy of trigeminal neuralgia. Clinical Journal of Pain 2002, 18(1):22-27
14. McQuay H and Moore A An evidence-based resource for pain relief. Oxford University Press, Oxford, New York 2000, 14:
15. Sommer C, Schafers M, Marziniak M and Toyka KV Etanercept reduces hyperalgesia in experimental painful neuropathy. Journal of the Peripheral Nervous System 2001, 6(2):67-72
16. Goebel A, Steinbach H, Karch H, Schedel R, Arnold A, Roewer N and Sprotte G (Minimal seroconversion rates following antibiotic treatment of patients with chronic pain syndromes and IgA seroantibodies to Campylobacter jejuni or human pathogenic Yersiniae) (German). Der Schmerz 2001, 15(1):S71-S72
17. Farrar JT, Young JP, LaMoreaux L, Werth JL and Poole RM Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158
18. Ware JE, Snow KK Jr, Kosinski M and Gandek B SF-36 Health Survey Manual and Interpretation Guide. New England Medical Center, Boston, MA 1993,
19. Nelson EC, Landgraf JM, Hays RD, Wasson JH and Kirk JW The functional status of patients: how can it be measured in physicians' offices? Medical Care 1990, 28:1111-1126
20. Hürny Ch, Jürg B, Bacchi M, van Wegberg B, Tomamichel M, Spek U, Coates A, Castiglione M, Goldhirsch A and Senn HJ The perceived adjustment to chronic illness scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Supportive Care in Cancer 1993, 1:200-208
21. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST and McCrosky S A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. The New England Journal of Medicine 1993 329(27):1993-2000
22. Moore RA, Commins DJ, Bates G and Phillips CJ S-carboxymethylcysteine in the treatment of glue ear: quantitative systematic review. BMC Family Practice 2001, 2:3
23. Phillips CJ, Burrell A, Moore RA, Bates GJ and Commins D Mucodyne: the economics of preventing surgery for grommets. Journal of Medical Economics 1999, 2:167-176